Optimization of VNS in Epileptic Patients to Induce Cardioprotection
This study is a non-randomized, prospective study in patients with a diagnosis of epilepsy and previously implanted FDA approved Vagus Nerve Stimulation (VNS) devices. The goal of this clinical investigation is to evaluate the effects of adjusting vagus nerve stimulation parameters to engage cardioprotective effects.
- Clinical diagnosis of refractory epilepsy and implanted with a VNS device or are scheduled to be implanted with a VNS device.
- 18 years of age or older
- Subjects must demonstrate willingness and ability to comply with study requirements
- Other implantable neuromodulatory device (e.g., brain stimulator)
- Treatment with cholinergic or anticholinergic medication in the past month
- Pre-existing cardiac arrhythmia or presence of cardiac pacemaker/defibrillator
- History of dysautonomias
- History of vasovagal syncope
- Progressive neurological diseases other than epilepsy
- Women that are pregnant
- Cognitive or psychiatric deficit that in the investigator's judgment would interfere with the subject's ability to accurately complete study assessments